Acute Vulvovaginal Candidiasis Treatment Market,By Drug Type, By Route of Administration, By Distribution Channel, By Geography

Description

Acute Vulvovaginal Candidiasis Treatment Market is estimated to be valued at USD 1,050 Mn in 2026 and is expected to reach USD 1,470 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,050 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.20%	2033 Value Projection:	USD 1,470 Mn

Acute vulvovaginal candidiasis is a yeast infection, which affects the vagina and tissues present at the opening of the vulva. It is caused by fungus Candida species. The symptoms for the infection are intense itchiness, inflammation, thick, white discharge, and others. Mild infection can be cured with a single dose of the antifungal agent or by application of antifungal creams while severe infections require longer treatment.

Market Dynamics

Market players are indulged in inorganic activities such as acquisition, which is expected to expand their product portfolio and strengthen their position in the global market, and drive growth of the global market over the forecast period. For instance, on June 7, 2020, ANI Pharmaceuticals Inc. acquired Fluconazole Tablets (50mg, 100mg, 150mg, and 200mg) from a private company for US$ 3 million. Thus, ANI Pharmaceuticals expanded their product portfolio by including drugs for the treatment of acute vulvovaginal candidiasis.

Increasing research and development for developing treatment for vulvovaginal candidiasis is expected to drive growth of the global acute vulvovaginal candidiasis treatment market over the forecast period. For instance, according to the article published in the BMC Microbiology Journal: 2018, Nystatin, an oral medication for the treatment of vulvovaginal candidiasis, when used in the vaginal epithelial cells (VEC) infected with Candidiasis albicans, increased the levels of IFN-Y, IL-17, and IgG in the cells as compared to the uninfected cells. Therefore, Nystatin upregulates the host defense mechanism against Candida albicans.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global acute vulvovaginal candidiasis treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global acute vulvovaginal candidiasis treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the acute vulvovaginal candidiasis treatment market

Acute Vulvovaginal Candidiasis Treatment Market Segmentation

By Drug Type (Revenue, USD Mn, 2021-2033)
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration (Revenue, USD Mn, 2021-2033)
- Oral
- Intravenous
- Topical
By Distribution Channel (Revenue, USD Mn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Acute Vulvovaginal Candidiasis Treatment Market, By Region (Revenue, USD Mn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- Mycovia Pharmaceuticals, Inc.
- Scynexis, Inc.
- Basilea Pharmaceutica Ltd.
- Astellas Pharma Inc.
- Grupo Ferrer Internacional, S.A.
- Pacgen Life Science Corporation
- NovaDigm Therapeutics, Inc.
- Cidara Therapeutics, Inc.
- Amplyx Pharmaceuticals Inc.
- Pfizer, Inc.

Product Code: CMI4315

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type
- Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration
- Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel
- Global Acute Vulvovaginal Candidiasis Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trend

4. Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Clotrimazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Nystatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Fluconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Ketoconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Terbinafine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Terconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Acute Vulvovaginal Candidiasis Treatment Market, By Region, 2021 - 2033, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2026 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Mycovia Pharmaceuticals, Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Scynexis, Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Basilea Pharmaceutica Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Astellas Pharma Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Grupo Ferrer Internacional, S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pacgen Life Science Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
NovaDigm Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cidara Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amplyx Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer, Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

9. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. References and Research Methodology

References
Research Methodology
About us